Cantor Fitzgerald reiterated its Buy rating on Sirona Dental Systems SIRO and increased its price target from $57 to $60.
Cantor Fitzgerald noted, "With the recent launch of CEREC Omnicam, we highlight BUYrated Sirona as our top mid-cap medtech pick and raise our target from $57 to $60. While challenges exist (currency, Europe, near-term gross margin pressure), we view Omnicam as a game-changing technology that we believe will spark a new product cycle and drive broader adoption in this vastly under-penetrated market. Despite its recent strength (+23% since July 31 vs. +2% for the S&P), SIRO still trades at a slight discount to its peer group. With a market-leading new product and a likely return to positive operating leverage and double-digit EPS growth in 2013, we think a premium is warranted."
Sirona Dental Systems closed at $53.13 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in